Comparative Pharmacology
Head-to-head clinical analysis: OPANA ER versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPANA ER versus TALWIN.
OPANA ER vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic